ICFSR has applied for AMA PRA Category 1 credit

KEYNOTES Learning objectives:

Keynote 1: Heike Bischoff- Ferrari (Zurich University, Switzerland)

Do-Health Trial

Learning objectives
• Describe the DO-HEALTH as a multicenter trial to prolong healthy life expectancy in European seniors
• Discuss whether vitamin D, omega-3 fatty acids, and a simple home exercise program will prevent disease at older age
• Discuss the implications of the Do-Health Trial for future research and routine clinical practice

Keynote 2: Matteo Cesari (Granda-Universita di Milano, Italy)

Intrinsic capacities

Learning objectives
• Describe Intrinsic capacity as the combination of the individual’s physical and mental, including psychological, capacities
• Discuss strategies for maintaining intrinsic capacity and functional ability across the life course
• Identify markers of declines in intrinsic capacity, such as decreased gait speed or muscle strength

Keynote 3: Shanlender Bhasin (Harvard Medical School, Boston, USA)

Effect of Protein Intake on Muscle Mass, Performance and Physical Function in Functionally-Limited Older Adults

Learning objectives
• Describe the evidence for the effects of protein intake in older adults with physical function limitations
• Discuss whether increasing protein intake in older adults with physical function limitations and usual protein intake improves lean body mass (LBM), muscle performance, physical function
• Formulate an approach for recommendations of protein intake in older adults with physical function limitations

Keynote 4: Bill Evans (Duke University, Durham, USA)

Biomarkers for sarcopenia

Learning objectives
• Summarize the evidence on available biomarkers (functional, biological, or imaging-related) that could be utilized in clinical trials of sarcopenia
• Discuss the currently available parameters that could be utilized in clinical trials of sarcopenia
• Formulate a framework for the cost-effective use of biomarkers that can guide the diagnosis and therapy of sarcopenia in routine clinical practice and clinical trials

Keynote 5: Jeremy Walston (John Hopkins University, Baltimore, USA)

Biomarkers and biology of frailty

Learning objectives
• Discuss biological processes linked to frailty and their corresponding biomarkers
• Identify potential associations between frailty and biomarkers
• Association of Frailty with biomarkers of inflammation

CME course Learning objectives:

When leaving the conference the participants will be able to:

  • Define sarcopenia and frailty
  • Interpret the effect of nutrition in functionally-limited older adults
  • Evaluate frailty and sarcopenia in routine care management of older people
  • Recognize the consequences and complications of frailty and sarcopenia to apply to routine clinical practice
  • Asses the importance of vitamin and nutrition in the routine management of frail individuals
  • Integrate physical activity in the care pathways of frail individuals
  • Assess cognitive decline in frail older people



Keynote 1Heike Bischoff-Ferrari


Zurich University,

Do-Health Trial

Keynote 2Matteo Cesari


di Milano,

Intrinsic capacities

Keynote 3Shalender Bhasin

Shalender Bhasin

Harvard Medical School,
Boston, USA

Effect of Protein Intake on Muscle Mass, Performance and Physical Function in Functionally-Limited Older Adults

Keynote 4Bill Evans


Duke University,

Biomarkers for sarcopenia

Keynote 5Jeremy Walston

Jeremy Walston

Johns Hopkins University,

Biomarker and biology of Frailty


The Management of Frailty in Clinical Practice –
A Frailty PRIMER

ICFSR 2019 Course Friday, February 22nd, 2019 Miami Beach, Florida, USA

9:00 AM 1. The Frailty Syndrome Jeremy Walston, MD
Johns Hopkins University, USA
9:30 AM 2. Consequences and Complications Alfonso J. Cruz-Jentoft, MD, PhD
Hospital U Ramón y Cajal, Spain
10:00 AM 3. The Role of Nutrition and Vitamin D Heike A. Bischoff-Ferrari, MD, DrPH
University Hospital Zurich
10:30 AM BREAK       
11:00 AM 4. The Role of Exercise & Physical Activity Marco Pahor, MD
Institute on Aging, U of Florida, USA
11:30 AM 5. The Role of Pharmacological Therapies Matteo Cesari, MD, PhD
U degli Studi di Milano, Italy
12:00 PM 6. Goals of Care and Palliative Care Michael J. Mintzer, MD
U of Miami and VA GRECC, USA
12:30 AM LUNCH       
1:30 PM 7. The Management of Sarcopenic Obesity Roger Fielding, PhD
Tufts University, USA
2:00 PM 8. Cognitive Frailty Luis Miguel Gutiérrez, MD
National Institute of Geriatrics, Mexico
2:30 PM 9. Prevention of Frailty Bruno Vellas, MD
Toulouse University Hospital, France
3:00 PM 10. Clinical Models Jorge G. Ruiz, MD
U of Miami and VA GRECC, USA


Panel Discussion 1:

Panel discussion on definition for Sarcopenia

Presentation: Alfonso Cruz Jentoft (Madrid - Spain)

Panel Discussion: Marco Pahor (Gainesville - USA), Yves Rolland (Toulouse-France), Matteo Cesari (Milan - Italy) , Roger Fielding (Boston - USA)

Panel Discussion 2:

Panel discussion on International Clinical Practice Guidelines for Sarcopenia (ICFSR): Screening, Diagnosis and Management

Panel Discussion: John Morley (Saint Louis- USA), Elsa Dent (Adelaide - Australia)


• Latest information on NIA’s research and related programs from other federal agencies
Rosaly Correa-de-Araujo, M.D., M.Sc., Ph.D.
National Institute on Aging, National Institutes of Health
U.S. Department of Health and Human Services
(Bethesda, USA)

• Selection of relevant outcomes in sarcopenia: a Discrete Choice Experiment
Chairpersons: Mickaël Hiligsmann, Charlotte Beaudart
Welcome and introduction: Jean-Yves Reginster Identification and prioritization of important outcomes for patients in sarcopenia – Charlotte Beaudart
Results from the cross-European Discrete Choice Experiment – Mickaël Hiligsmann Discussion (Leader: Fanny Buckinx): Islene Araujo de Carvalho, Jürgen Bauer, Charlotte Beaudart, Olivier Bruyère, Cyrus Cooper, Alfonso Cruz-Jentoft, Mickaël Hiligsmann, Jean-Marc Kaufman, Jean-Yves Reginster, René Rizzoli. Conclusion: Olivier Bruyère

• Osteosarcopenic obesity : enough evidence for a distinct entity?
Chairpersons: Islene Araujo de Carvalho, Roger Fielding.
Welcome and introduction: Jean-Yves Reginster
Osteosarcopenia obesity: Facts and evidence supporting a distinct entity - Jürgen Bauer
Osteosarcopenic obesity: Lack of facts and evidence supporting a distinct entity – Alfonso Cruz Jentoft
Discussion (Leader: René Rizzoli): Islene Araujo de Carvalho, Jürgen Bauer, Olivier Bruyère, Cyrus Cooper, Alfonso Cruz Jentoft, Roger Fielding, Jean- Marc Kaufman, Médéa Locquet, Jean-Yves Reginster.
Conclusion: Cyrus Cooper